{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit was not calculable because an insufficient number of participants reached the event at the final time point for assessment.","groupId":"OG000","lowerLimit":"12.3","upperLimit":"NA","value":"37.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from registration to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Lenalidomide (Len) 15mg daily (days 1-21); Cyclophosphamide (Cyc) 300 mg/m\\^2 (days 1, 8, 15); Dexamethasone (Dex) 40 mg weekly","id":"OG000","title":"Len/Cyc/Dex"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Duration of study (up to 3 years)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}